Skip to main content
ARTL
NASDAQ Life Sciences

Artelo's ART26.12 Pain Treatment Gains Peer-Reviewed Validation, Advances to Next Clinical Study

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5.708
Mkt Cap
$4.165M
52W Low
$2.955
52W High
$85.8
52W Position info
93% above low
Off High info
93% below high
Rel. Volume
Market data snapshot near publication time

ARTL sits 93% above its 52-week low of $2.955.

Summary

Artelo Biosciences announced the publication of a peer-reviewed article supporting its FABP5 inhibitor, ART26.12, as a novel pain treatment with a potentially first-in-class profile. The publication highlights preclinical evidence of ART26.12's analgesic effects across multiple pain models and its differentiated, non-opioid approach. The company also noted that its completed Phase 1 single ascending dose (SAD) study for ART26.12 demonstrated excellent safety with no drug-related adverse events. This scientific validation strengthens the drug's profile and supports its advancement into a planned multiple ascending dose (MAD) study this year. For a clinical-stage biotech with a small market capitalization, this positive scientific endorsement and progress in a key pipeline asset is a material development, providing increased confidence in the drug's potential.

At the time of this announcement, ARTL was trading at $5.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $2.96 to $85.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ARTL - Latest Insights

ARTL
Nov 12, 2026, 8:00 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.24
Real-time Price: $2.26 info
Change: +$0.020 (+0.89%) info
Market Cap: $1.15M info
ARTL
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.19
Real-time Price: $2.26 info
Change: -$0.930 (-29%) info
Market Cap: $1.15M info
ARTL
Sep 23, 2026, 1:46 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $7.84
Real-time Price: $2.26 info
Change: -$5.58 (-71%) info
Market Cap: $1.15M info
ARTL
Sep 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.02
Real-time Price: $2.26 info
Change: -$2.76 (-55%) info
Market Cap: $1.15M info
ARTL
Aug 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.658
Real-time Price: $2.26 info
Change: Reverse Stock Split info
Market Cap: $1.15M info